PTC Therapeutics Inc (NASDAQ: PTCT), a science-driven, global biopharmaceutical company, announced its financial results for 2019 on Monday.

The company reported total revenues of USD307m in 2019 compared to USD264.7m in 2018.

The firm posted net loss at USD251.6m or 4.27 per basic and diluted share in 2019, compared to a net loss of USD128.1m or 2.75 per basic and diluted share in 2018.

Stuart Peltz, PhD, PTC Therapeutics' CEO, said, '2019 was a year of outstanding execution for PTC. I'm proud of the progress made in every area of the business. We've significantly expanded our rare disease portfolio, strengthened our global commercial engine and added vital gene therapy manufacturing capabilities, all while delivering on our revenue guidance. The innovation in our diverse, multiplatform pipeline continues to create value for stakeholders.'